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Filip Van Nieuwerburgh  
To allow multiple genetic analyses on a single cell, whole genome amplification (WGA) is required. 
Unfortunately, studies comparing different WGA methods for downstream human identification 
Short Tandem Repeat (STR) analysis remain absent. Therefore, the aim of this work was to assess 
the performance of four commercially available WGA kits for downstream human identification STR 
profiling on a B-lymphoblastoid cell line. The performance was assessed using an input of one or three 
micromanipulated cells. REPLI-g showed a very low dropout rate, as it was the only WGA method in this 
study that could provide a complete STR profile in some of its samples. Although Ampli1, DOPlify and 
PicoPLEX did not detect all selected STR markers, they seem suitable for genetic identification in single-
cell applications.
Whole genome amplification (WGA) is inevitable to allow multiple genetic analyses on either a single cell or a 
limited number of cells. WGA increases the amount of input-DNA from pg-level up to ng- or µg-level. However, 
it is well known that several WGA methods introduce bias during amplification and thereby influence the results 
of downstream genetic analyses1,2. The nature of the introduced bias depends on the WGA method that is used. 
Therefore, a WGA method must be selected according to the required downstream application. Some meth-
ods will result in a non-uniform coverage, while others will introduce more nucleotide errors3. Recently, many 
researchers have studied the effect of WGA on copy number variant (CNV) analysis4–8 and targeted genotyping 
analysis9. However, studies comparing different WGA methods for human identification Short Tandem Repeat 
(STR) analysis of a single cell or a limited number of cells remain absent.
The growing interest in single-cell analysis for clinical applications raises the need to identify single cells. Such 
a genetic analysis that is often performed on only a limited number of cells is STR analysis for human identifi-
cation DNA profiling. STRs are short DNA-fragments with different lengths (between 100 and 500 base pairs) 
within the population. A multiplex-PCR is executed to analyze a standard set of STR loci and to create an STR 
profile. Except for identical twins, each person has a unique STR profile. Therefore, single-cell DNA profiling is 
particularly valuable in the context of cell-based non-invasive prenatal testing (cbNIPT). As no specific fetal cell 
marker has been discovered so far, after the isolation of a single fetal cell from a maternal blood sample, the fetal 
identity of this cell needs to be confirmed prior to further downstream procedures. In this way, maternal cell con-
tamination in the sample can be excluded. Other clinical applications, such as preimplantation genetic diagnosis 
(PGD), might also apply STR analysis to assure the nature of the isolated cells10. After fetal confirmation, genetic 
analysis such as CNV analysis is performed on this unique cell. Hence, to allow both STR and CNV analysis on a 
single cell, WGA is required.
Unfortunately, a WGA method that is ideal for STR genotyping might be less suitable for CNV analysis. For 
example, previous research by Denis et al. demonstrates that multiple displacement amplification (MDA) WGA 
might be applicable for STR analysis10. In contrast, MDA is not considered the most preferable WGA method for 
CNV analysis6. The aim of this study was to assess the performance of four commercially available WGA kits for 
downstream human identification STR on a B-lymphoblastoid cell line. REPLI-g Single Cell Kit, PicoPLEX WGA 
Kit, Ampli1 WGA Kit and DOPlify WGA were compared in parallel for their ability to produce WGA product, 
adequate for human identification STR analysis. The same WGA methods have been tested before in a similar 
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experimental setup to assess their performance to produce a WGA product, adequate for CNV analysis6. REPLI-g 
single cell kit (Qiagen, Hilden, Germany) is based on this MDA mechanism and has already been shown useful 
for STR analysis10. PicoPLEX WGA Kit (Rubicon Genomics Inc., MI 48108, USA) is a hybrid MDA-PCR-based 
WGA method that uses self-inert degenerate primers. During the multiple displacement pre-amplification step, 
an in vitro hairpin template library is created, which is then amplified in a PCR reaction using flanking univer-
sal priming sites. PicoPLEX WGA kit has been widely used and the suitability of this kit for CNV analysis on a 
limited number of cells has been proven by several studies3,11,12. Ampli1 WGA Kit (Silicon Biosystems, Castel 
Maggiore, Italy) is a ligation-adapter PCR-based WGA method that utilizes a frequent cutter restriction enzyme 
for the initial fragmentation of the DNA template. One single highly specific primer, complementary to the adapt-
ers that are ligated on both sides of each DNA fragment, initiates the subsequent PCR amplification reaction. 
This ligation-based WGA method has already been successfully applied in a cbNIPT context11. The most recently 
developed DOPlify WGA (Reproductive Health Science, Thebarton, Australia) uses an advanced Degenerate 
Oligonucleotide Primed PCR (DOP-PCR). In the past, the classical DOP-PCR did not result in reliable CNV or 
STR analysis13. Nevertheless, DOPlify Reaction Kit is an advanced version of this classical DOP-PCR and has 
recently shown promising results for CNV analysis, with minimal bias introduction6. This kit has not yet been 
tested in the context of STR profiling.
Samples consisting of one or three cells, in triplicate, were collected from a B-lymphoblastoid cell line (B-LCL) 
using micromanipulation. As many clinical applications are based on single-cell analysis, single-cell samples are 
used as input in this study. Three-cell samples are included to detect possible differences in the performance of 
STR analysis after WGA on a few cells compared to a single cell. The lymphoblastoid cell line is representative 
for most human cells and is ideal as a reference for STR analysis, as it is diploid without any genomic aberrations. 
The samples were amplified using the four above-mentioned WGA kits and for each sample, a selection of 14 STR 
loci and the Amelogenin locus were amplified in a multiplex PCR reaction. A bulk DNA sample from the B-LCL 
was included in the STR-PCR reaction and used as a reference STR-profile against which all sample results were 
compared.
Materials and Methods
Experimental design. In this study, the performance of four WGA kits was examined for STR-genotyping 
on a limited number of cells from a male B-lymphoblastoid cell line (B-LCL), NA12882. This suspension cell line 
allowed the isolation of individual cells, using micromanipulation. Samples consisting of one or three cells, in 
triplicate, were collected for each WGA method. In parallel, a bulk DNA sample from the cell line was extracted. 
The 1- and 3-cell samples were amplified using Ampli1 WGA Kit (Silicon Biosystems, Castel Maggiore, Italy), 
DOPlify WGA (Reproductive Health Science, Thebarton, Australia), REPLI-g Single Cell Kit (Qiagen, Hilden, 
Germany) and PicoPLEX WGA Kit (Rubicon Genomics Inc., MI 48108, USA). STR-genotyping was performed 
on all WGA amplified DNA samples and the bulk sample. The STR-profile from the bulk DNA sample served as 
a reference to which all STR-profiles were compared (Fig. 1).
A positive control sample containing 1 ng male human genomic 2800 M Control DNA (Promega, Wisconsin, 
USA) was included during PCR to verify the success of the STR-multiplex PCR reaction. A negative control, con-
sisting of H2O, was included to detect contamination introduced during the STR-PCR.
Cell culture and isolation. The B-lymphoblastoid cell line (NA12882), acquired from Coriell Institute 
for Medical Research (Camden, USA), was grown in Roswell Park Memorial Insititute (RPMI-1640) medium 
(Life technologies, Carlsbad, USA). This cell medium was supplemented with 15% fetal bovine serum (Life 
Technologies, Carlsbad, USA), 2 mM L-glutamine (Life technologies, Carlsbad, USA) and a mix of penicillin at 
100 units/mL and streptomycin at 100 µg/mL (Life technologies, Carlsbad, USA). Cells were cultured at a temper-
ature of 37 °C and a 5% CO2 level. Cells were micromanipulated in a similar fashion as described by Deleye et al.6, 
except for the storing of the cells on ice after isolation. A bulk DNA sample from the NA12882 cell line was 
Figure 1. Schematic overview of the experimental design.
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prepared using the DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany) on ± 5*106 cells, following manufac-
turer’s instructions.
Whole genome amplification. Cell lysis and amplification using Ampli1 WGA Kit (Silicon Biosystems, 
Castel Maggiore, Italy), DOPlify WGA (Reproductive Health Science, Thebarton, Australia), REPLI-g Single 
Cell Kit (Qiagen, Hilden, Germany) and PicoPLEX (Rubicon Genomics Inc., MI 48108, USA) WGA Kit, was 
performed according to manufacturer’s instructions. A positive control containing ±30 pg high quality DNA 
(Human Genomic DNA, Roche, 100 µg (500 µl)) was included during each WGA reaction. A negative control, 
consisting of 1 µl of H2O, was added to exclude possible contamination during WGA. Purification of the amplified 
DNA was performed, using the Genomic DNA Clean & Concentrator kit (version 1.0.0, Zymo Research, Irvine, 
USA) following manufacturer’s recommendations. Qubit dsDNA High Sensitivity Assay kit (Life technologies, 
Carlsbad, USA) was used to determine DNA concentration.
STR-genotyping. STR-genotyping was performed using an in-house developed multiplex STR-PCR, 
based on the forensic Promega Powerplex 16 kit. This multiplex-PCR was used to simultaneously amplify 14 
STR loci across the human genome in each sample: D3S1358, TH01, D21S11, D18S51, vWA, D8S1179, TPOX, 
FGA, D5S818, D13S317, SE33, CD4, D7S820, D16S539, and the Amelogenin locus for sex determination. 
The PCR reaction mix contained 2.5 U Hotstar Taq polymerase (Qiagen, Hilden, Germany), 0.5 mM MgCl2 
(Qiagen, Hilden, Germany), 0.4 µg/µL albumin (Sigma-Aldrich, Saint Louis, USA), 1× PCR buffer (Qiagen, 
Hilden, Germany), 0.15 µM–1 µM of each primer and 30 µL of purified DNA, in a total end volume of 50 µl. 
Supplementary Table S1 shows the exact concentrations used for each primer. For Ampli1, DOPlify, REPLI-g and 
PicoPLEX respectively 1 ng, 1 ng, 4 ng and 5 ng purified amplification product was added to the reaction mixture. 
The multiplex-PCR consisted of three steps: an initial denaturation step (95 °C, 15 min), 28 amplification cycli 
(94 °C, 1 min; 58 °C, 1 min; 72 °C, 1 min 20 s) and a final elongation step (72 °C, 10 min) and was performed in a 
SimpliAmp Thermal Cycler (Life Technologies, Carlsbad, USA).
STR Genotyping analysis. STR profiles were generated with fragment size capillary electrophoresis using 
the ABI 3500 Genetic Analyzer equipped with GeneMapper ID-x 1.2 fragment size analysis software (Applied 
Biosystems, Carlsbad, USA) following manufacturer’s recommendations. Allele peaks were indicated by main-
taining a detection threshold of 50 RFU. The dropout rate (DO%) was assessed for all samples and compared 
Figure 2. Overview of dropouts in STR profiles for each WGA method. This figure illustrates which loci 
were called in each sample compared to the reference profile. Green represents correctly called loci; Orange 
represents an allelic dropout at a heterozygous locus; Red indicates a complete locus dropout.
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between the four WGA methods as well as between the 1- and 3-cell samples per WGA method. The DO% indi-
cates how many of the expected alleles are present or missing in the sample STR profiles. The dropout rate was 
calculated, based on equation (1).




−










×
total number of observed alleles
total number of expected alleles
1 100%
(1)
Results and Discussion
DNA yield. After WGA, the DNA yield was assessed and compared between the four WGA methods 
(Table 1). The yield was similar for Ampli1, DOPlify and PicoPlex, except for two single cell samples from 
Ampli1. All samples, except those two, contained ±1000 ng of DNA. The yield after REPLI-g was considerably 
higher than the other WGA methods. Yields after either one- or three-cell amplification do not differ significantly 
for all tested WGA methods.
The absence of contamination after Ampli1, DOPlify and PicoPLEX WGA was proven by the negligible DNA 
yield in their respective negative control. However, the negative control from REPLI-g resulted in a concentration 
of more than 1000 ng/µl. According to the kit’s manual, the presence of high DNA yield in negative controls is 
caused by the random extension of primer dimers in the absence of a template, generating high-molecular-weight 
product. The yield for all positive controls was similar to the yield of the cell samples of the corresponding WGA 
methods.
Overall, the yield after WGA did not indicate any problems during amplification and was certainly high 
enough to perform both STR analysis and other conceivable downstream genetic analyses.
Dropouts in STR profiles. The STR profiles of the samples were compared to the reference STR profile of 
the bulk sample from the NA12882 cell line. The reference profile and the profiles of all samples are shown in 
Supplementary Figure S1 and S2 respectively. Figure 2 shows for each sample which loci were called in accord-
ance to the reference. Green represents correctly called loci, orange represents an allelic dropout at a heterozygous 
locus, and red indicates a complete locus dropout. The dropout rate was calculated for each sample. The average 
dropout rate and standard deviation for the different WGA methods is shown in Fig. 3.
For REPLI-g WGA, the generated STR profiles were almost identical to the reference profile. Consequently, 
the dropout rate for single- and three-cell samples amplified with REPLI-g was only 8.33% ± 11.48 and 
2.38% ± 2.06, respectively. One single-cell sample showed two locus dropouts and three allelic dropouts, while the 
other REPLI-g samples showed no or maximum one dropout in their STR profile. The dropout rate for samples 
amplified with Ampli1, DOPlify and PicoPLEX was distinctly higher compared to REPLI-g. In the Ampli1 sam-
ples, the dropout seems consistent for certain loci, as a recurrent locus dropout of the same 6 loci was observed in 
almost all samples. No alleles were detected in all Ampli1 samples for D18S51, AMEL, D8S1179, TPOX, FGA and 
D7S820 with exception of one single-cell sample showing an allelic dropout for FGA instead of a locus dropout. 
The dropout rate for single- and three-cell Ampli1 amplification was 60.71% ± 22.30 and 44.05% ± 2.06, respec-
tively. The dropout after PicoPLEX and DOPlify WGA seemed more random across the different loci, although 
some consistency among the samples was noticeable. A dropout for the vWA and D5S818 locus was observed in 
almost all PicoPLEX samples, whereas for DOPlify almost all samples showed a dropout for TPOX, D7S820 and 
D16S539. After PicoPLEX WGA, one sample failed to show an STR profile. Therefore, this sample was omitted 
from the dropout rate calculation for PicoPLEX. Apart from this sample, PicoPLEX samples showed less drop-
outs compared to both Ampli1 and DOPlify with a dropout rate of 35.71% ± 3.57 after single-cell amplification 
and 16.07% ± 0.00 after three-cell amplification. The dropout rate for DOPlify was 59.52% ± 12.54 for single-cell 
samples, whereas for three-cell samples a dropout rate of 34.52% ± 2.06 was calculated.
Previous studies already indicated that MDA is suitable for STR analysis, but no comparison has been made 
with other modern WGA techniques. We observed that the MDA method used in this study, REPLI-g, was the 
only WGA that resulted in complete STR profiles for some of its samples. Because of the branched network for-
mation during WGA, this MDA technology amplifies more regions. Therefore, it is more likely that all STR loci 
are included during amplification. The recurrent locus dropout of Ampli1 may also be related to its WGA work-
ing mechanism. The restriction enzyme might cleave at the STR primer binding sites of these loci, which inhibits 
their amplification. Therefore, the results for Ampli1 could possibly improve if other loci were selected for STR 
analysis. PicoPLEX showed slightly better results than both Ampli1 and DOPlify, but the amplification protocol 
seems less robust, as one of its samples failed to show an STR profile. The pre-amplification during the PicoPLEX 
amplification protocol uses the MDA technology, which might explain why PicoPLEX is the second best WGA for 
STR analysis. However, PicoPLEX uses another polymerase than the one used by REPLI-g and no large, branched 
network is formed during pre-amplification. The four WGA methods showed a slightly better STR profile and 
less variability between individual samples after three-cell amplification compared to single-cell amplification.
Nevertheless, in the context of cell-based NIPT, fetal cell identification would also be possible from a partial STR 
profile. Therefore, Ampli1, PicoPLEX and DOPlify are also suitable for genetic identification in cell-based NIPT 
or other clinical genetic identification purposes, despite the fact that in most samples only half of the STR markers 
were detected. In cell-based NIPT or PGD, the WGA products are mainly intended for downstream genetic analysis, 
such as CNV detection. Therefore, beside STR analysis the WGA product must also be suitable for CNV analysis. 
REPLI-g showed its suitability for CNV detection on a limited number of cells at a resolution of 3 Mb earlier, but 
did introduce some representation bias6. DOPlify introduced almost no representation bias for CNV calling in that 
context, but its STR profiling resulted in more dropouts compared to REPLI-g. Both Ampli1 and PicoPLEX showed 
slightly more representation bias compared to DOPlify for CNV calling, but less compared to REPLI-g.
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Conclusion
We can conclude that DNA from a limited number of B-lymphoblastoid cells is suitable for STR profiling after 
WGA, but the quality of the results will depend on the selected WGA method. REPLI-g has a very low dropout 
rate and is the only method in this study that can provide a complete STR profile in some of its samples. Although 
Ampli1, DOPlify and PicoPLEX do not detect all selected STR markers, they also seem suited for genetic identi-
fication in clinical single-cell applications.
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